Jiuzhou Pharmaceutical(SH:603456) Xin Lang Cai Jing·2025-11-14 02:45Core Viewpoint - Jiuzhou Pharmaceutical has seen a significant stock price increase, with a 5.31% rise on November 14, reaching 21.42 yuan per share, and a total market capitalization of 19.052 billion yuan, indicating strong investor interest and performance in the market [1]. Company Overview - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, is located in Taizhou, Zhejiang Province. The company specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1]. - The revenue composition of Jiuzhou Pharmaceutical includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1]. Shareholder Insights - Among the top circulating shareholders of Jiuzhou Pharmaceutical, a fund under China Europe Fund has increased its holdings. The China Europe Medical Health Mixed A Fund (003095) added 3.9767 million shares in the third quarter, bringing its total to 17.403 million shares, which represents 1.96% of the circulating shares [2]. - The fund has realized a floating profit of approximately 18.7952 million yuan today, with a total floating profit of 15.8367 million yuan during the four-day stock price increase [2]. Fund Manager Performance - The fund manager of China Europe Medical Health Mixed A, Ge Lan, has a tenure of 10 years and 293 days, with a total fund size of 43.544 billion yuan. The best return during her tenure is 109.26%, while the worst is -35.13% [3]. - Co-manager Zhao Lei has been in position for 134 days, managing a fund size of 32.954 billion yuan, with a best return of 8.82% and a worst return of 8.51% during his tenure [3].